23 December 1976 Mammographic Screening For Breast Cancer: Three Years to Date What Have We Wrought?
Author Affiliations +
Proceedings Volume 0096, Application of Optical Instrumentation in Medicine V; (1976) https://doi.org/10.1117/12.965458
Event: Application of Optical Instrumentation in Medicine V, 1976, Washington, D.C., United States
Abstract
Analysis of the data of the Health Insurance Plan of New York Breast Cancer Screening Study indicates that in those patients whose cancers were found by screening the case fatality rate at all ages is almost half the case fatality rate of controls. Those data also indicate maximal benefit in young women resides in the detection of in situ cancers. Due to relatively low yield of these early lesions, CFR and projected 20-year survival is no different for all women screened from controls. We have shown that the yield of these early lesions can be maximized by aggressive screening and liberal use of biopsy. Twenty-year survival after a five-year screen can be raised 30 percent above HIP control level and as much as 70 percent above HIP screened level. Furthermore, where Bailar has indicated a net gain (or loss) from -4 to +8 lives/20,000 women using the HIP data, using his method and our data we find a savings of 25-27 lives/20,000 women by three year screening to date. These are lives that have been saved by mammography alone.
© (1976) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Myron Moskowitz, Myron Moskowitz, Peter Gartside, Peter Gartside, Linda Gardella, Linda Gardella, Deborah Guenther, Deborah Guenther, } "Mammographic Screening For Breast Cancer: Three Years to Date What Have We Wrought?", Proc. SPIE 0096, Application of Optical Instrumentation in Medicine V, (23 December 1976); doi: 10.1117/12.965458; https://doi.org/10.1117/12.965458
PROCEEDINGS
10 PAGES


SHARE
Back to Top